LATEST

    Vinco Ventures needs to get its act together as TikTok ban looms

    January 28, 2023

    BBBY’s latest 10Q has hidden text – Easter Egg or mistake?

    January 27, 2023

    Ross Miller is officially the new (sole) CEO of Vinco Ventures (BBIG)

    September 30, 2022

    If I buy BBIG stock now, will I get TYDE dividend?

    June 28, 2022

    GameStop posts Q1 FY22 results; beats revenue estimates

    June 1, 2022
    Legal
    Privacy Policy
    Cookie Policy
    Terms and Conditions
    Twitter Facebook Instagram YouTube LinkedIn
    Facebook Twitter Instagram YouTube LinkedIn
    Rising CandleRising Candle
    • Home
    • Market News

      Vinco Ventures needs to get its act together as TikTok ban looms

      January 28, 2023

      BBBY’s latest 10Q has hidden text – Easter Egg or mistake?

      January 27, 2023

      Vinco Ventures stock sinks after it delays Cryptyde spinoff

      May 25, 2022

      Enochian Biosciences (ENOB) stock crashes 40%

      May 25, 2022

      Sea Ltd (SE) stock gains over 10% on strong earnings

      May 17, 2022
    • Earnings
    • Business

      Ross Miller is officially the new (sole) CEO of Vinco Ventures (BBIG)

      September 30, 2022

      If I buy BBIG stock now, will I get TYDE dividend?

      June 28, 2022

      Wendy’s shares surge as potential takeover deal mulls

      May 25, 2022

      Snapchat (SNAP) crashes 30% after CEO warns missing EPS and revenue estimates

      May 24, 2022

      SIGA technologies (SIGA) stock gains as monkeypox cases rise

      May 23, 2022
    • Cryptocurrency
    • Forex
    Rising CandleRising Candle
    Home » Merck&Co. raises 2021 forecast, sees worldwide sales of $13.2 billion
    Earnings

    Merck&Co. raises 2021 forecast, sees worldwide sales of $13.2 billion

    Shushwi ShekharBy Shushwi ShekharNovember 11, 2021No Comments4 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    merck
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Merck raised it’s full year profit forecast in last week’s release. EBITDA is expected to increase between 26% to 29% in the full year, according to the announcement made on Thursday, 11th November, 2021.

    German Pharmaceuticals and chemicals company Merck reported a strong third quarter earnings report on 28th October, 2021- resulting in a 5% boost in stock prices the succeeding day. It is currently trading at $84.01.

    “This was driven by investments in our key growth pillars, particularly in supportive return to care activities and in our early and late-stage pipeline, including Molnupiravir (made in partnership with Ridgeback Biotherapeutics). Other expenses increased by approximately $200 million, reflecting higher pension settlement costs,”said Caroline Litchfield- Chief Financial Officer of Merck.

    Other key growth pillars for Merck were Keytruda (cancer powerhouse) and Gardasil which paved the way to a significantly exceeding earnings report. Cancer powerhouse Keytruda, which raked in sales of $4.5 billion, a 22% increase from third quarter in pandemic marred 2020.

    Meanwhile, Gardasil topped estimates by whopping $2 billion in sales, a 68% increase from 2020.The shot rebounded from supply issues and its pandemic-crippled performance in 2020.

    Providing information on the contribution of the vaccines in strong earnings, Merck CFO further announced that the company expects the global opportunity to be approximately $5 billion to $7 billion through 2022, including $0.5 billion to $1 billion expected to be realized this year. This assumes emergency use authorization in December.

    “If our post exposure prophylactic trial is successful, with an expected readout in the spring, there is potential upside to these estimates,” said Frank Clyburn, Merck’s president of human health.

    Merck generated revenue of $13.2 billion, a 20% increase from the same quarter a year ago. The revenue figure exceeded analysts estimates by a whopping $900 million. Earnings per share came in at $1.75, which topped the consensus estimate of $1.55.

    As a result, Merck raised its guidance that expects a sales growth of 14% to 15% and an annual revenue from a range of $46.4 to $47.4 billion to $47.4 to $47.9 billion.

    Merck made 17% growth in quarter 3, excluding the impact of foreign exchange.

    “In the fourth quarter, we will anniversary that effect, and we expect a more normalized year-over-year growth rate as a result. Our operating margin in the third quarter benefited from very strong revenue performance, including the normal seasonality of our vaccine business. As we move through the fourth quarter, we expect operating margins to normalize due to this seasonality and phasing of spend. More broadly, as we look out to 2024, we remain confident in our revenue potential and continue to believe it is underappreciated,”said Caroline Litchfield.

    As per the company’s website these are the Key Developments since Quarter third earnings report-

    On November 4, U.K.’s Medicines and Healthcare Products Regulatory Agency Authorized Molnupiravir for the Treatment of Mild-to-Moderate COVID-19 in Adults with a positive SARS-CoV-2 Diagnostic Test and who have at least One Risk Factor for Developing Severe Illness. Applications Remain Under Review by Other Regulatory Authorities, Including U.S. Food and Drug Administration and the European Medicines Agency.

    On November 8, Merck (NYSE: MRK), known as MSD outside the United States and Canada announced its pending acquisition of Acceleron Pharma Inc.

    (Nasdaq: XLRN) has been cleared by the competition authorities in Germany and Austria.Merck and Ridgeback announced on November 9 that the U.S. Government will purchase 1.4 Million additional courses of Molnupiravir, an investigational Oral Antiviral Medicine, for the treatment of Mild-to-Moderate COVID-19 in at-risk adults.

    On November 10, Merck and Ridgeback announced Japanese Government to purchase 1.6 Million courses of Molnupiravir, an investigational Oral COVID-19 antiviral medicine, upon authorization or approval.

    EBTIDA Merck Merck & Co Molnupiravir MRK Q3 Q3 earnings Q3 earnings 2021 Ridgeback
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Shushwi Shekhar

    Related Posts

    Vinco Ventures needs to get its act together as TikTok ban looms

    January 28, 2023

    BBBY’s latest 10Q has hidden text – Easter Egg or mistake?

    January 27, 2023

    GameStop posts Q1 FY22 results; beats revenue estimates

    June 1, 2022

    Snowflake reports Q1 results; Stock plunges due to narrow outlook

    May 26, 2022
    Add A Comment

    Comments are closed.

    Trending

    If I buy BBIG stock now, will I get TYDE dividend?

    June 28, 2022

    GameStop posts Q1 FY22 results; beats revenue estimates

    June 1, 2022

    Snowflake reports Q1 results; Stock plunges due to narrow outlook

    May 26, 2022

    Wendy’s shares surge as potential takeover deal mulls

    May 25, 2022

    Snapchat (SNAP) crashes 30% after CEO warns missing EPS and revenue estimates

    May 24, 2022

    Subscribe to Updates

    Get the latest Business and Finance news only at Investor's pulse

    Advertisement
    Editor's Picks

    AMC named ‘100 Most Influential Companies of 2022’ by Time Magazine

    March 31, 2022

    BuzzFeed released first earnings report after going public; revenue grew 24% YOY

    March 22, 2022

    U.S. jobless claims dip to a 2.5-month low

    March 17, 2022

    FOMC: Recent updates you need to know!

    March 17, 2022

    Your source for the latest US stock market and business news.

    Connect with us:

    Facebook Twitter Instagram YouTube LinkedIn Reddit

    Subscribe to Updates

    Subscribe to get weekly updates on what happened on the Stock Market and insights into where to invest.

    Legal
    Privacy Policy
    Cookie Policy
    Terms and Conditions
    © 2023 Investor's Pulse. All Rights Reserved.
    • Home

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Do not sell my personal information.
    Cookie SettingsAccept
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT
    Go to mobile version